Neurogenic Detrusor Overactivity: Symptoms, Causes, & Treatment

Neurogenic detrusor overactivity (NDO) is a bladder condition in which the muscle that squeezes urine out of the bladder contracts involuntarily because of an underlying neurological disease or injury. It differs from ordinary overactive bladder in one critical respect: the involuntary contractions are driven by damage to the brain, spinal cord, or nerves rather than by an unknown or idiopathic cause. NDO is common in people with spinal cord injuries, multiple sclerosis, Parkinson’s disease, stroke, and spina bifida, and when left unmanaged it can threaten kidney health as well as quality of life.

What NDO Feels Like

The hallmark symptoms of NDO are the same ones you would associate with any overactive bladder, but they tend to be more severe and harder to ignore. Urgency is the defining feature: a sudden, intense need to urinate that is difficult or impossible to defer. That urgency often leads to incontinence, where urine leaks before you can reach a bathroom. Many people with NDO also experience frequent urination during both day and night, and the volumes voided each time are small because the bladder contracts before it has filled to a comfortable level.

The severity of these symptoms depends heavily on where the neurological damage sits and on the specific underlying condition. Someone with a complete spinal cord injury may have no sensation of bladder filling at all, meaning they experience incontinence without any preceding urge. Someone with multiple sclerosis or Parkinson’s disease, by contrast, often feels the urgency acutely but cannot suppress it. In a urodynamic study comparing people with Parkinson’s disease to those with non-neurogenic overactive bladder, the Parkinson’s group had involuntary bladder contractions at significantly lower filling volumes, meaning their bladders began squeezing with less urine inside.¹

Neurological Causes

NDO is not a disease in itself. It is a consequence of damage somewhere along the chain of nerves and brain regions that normally keep bladder contractions under voluntary control. Any neurological condition that disrupts that chain can produce it, but certain diagnoses carry especially high risk.

Spinal Cord Injury

Spinal cord injury is one of the most common and most consequential causes. Damage to the cord disrupts communication between the brain’s voiding control centers and the bladder, leaving the bladder to contract on its own through spinal reflexes. Incontinence, urinary tract infections, stone formation, and kidney damage are all well-recognized complications.² Urodynamic evaluation is required for every patient with spinal cord injury because the severity of the injury alone does not reliably predict the type of bladder dysfunction that develops.³

Multiple Sclerosis

In MS, overactive bladder symptoms arise mainly because demyelinated plaques interrupt the inhibitory signals the brain normally sends down to the spinal cord to suppress voiding. The most commonly affected regions are the prefrontal and insular cortex, the brainstem, the cerebellum, and the cervicothoracic spinal cord. Lesions in the brain are thought to be the primary driver of detrusor overactivity, though spinal cord lesions in MS can also trigger a new reflex voiding pathway mediated by pain-sensing C-fiber nerves. Reduced serotonin activity and changes in stress hormones may further contribute.⁴

Parkinson’s Disease

In Parkinson’s disease, the loss of dopamine-producing neurons in the brain’s basal ganglia disrupts the complex circuits that keep voiding under voluntary control. The micturition reflex becomes partially disconnected from conscious regulation, leading to uninhibited bladder contractions. Neuroimaging studies have shown a decline in dopamine transporter activity in the brains of Parkinson’s patients who develop lower urinary tract symptoms, and animal research has demonstrated that disrupting the same dopamine pathway produces detrusor overactivity that can be reversed with dopamine receptor stimulators. Researchers have also found that overactivity of the adenosine A2A system in the brain may play a role, making A2A receptor antagonists a potential future treatment.⁴

Spina Bifida and Other Congenital Conditions

NDO is extremely common in children born with myelomeningocele, the most severe form of spina bifida. Neurogenic bladder affects up to 98% of these children, and among those studied with urodynamic testing, roughly half show detrusor overactivity while another 14% have detrusor-sphincter dyssynergia, a condition where the bladder and its outlet muscle work against each other.⁵

How the Brain Normally Keeps the Bladder in Check

Understanding NDO gets easier once you know the basics of how the brain controls voiding. Under normal circumstances, a region in the prefrontal cortex sends signals through the hypothalamus that tonically suppress the brainstem’s micturition center, known as the pontine micturition center or Barrington’s nucleus. This suppression keeps the bladder relaxed and prevents contractions until you consciously decide it is safe and socially appropriate to urinate.⁶ When a neurological injury knocks out any part of this inhibitory chain, the bladder is released from voluntary control and begins contracting on its own.

At the bladder wall itself, nerve fibers called C-fibers play an important role in NDO. In a healthy bladder, C-fibers are relatively quiet during normal filling. But after neurological injury or chronic obstruction, these fibers become hyperexcitable. Research using cold-water bladder testing has confirmed considerable C-fiber upregulation in people with neurogenic detrusor overactivity, and this heightened sensitivity of the afferent (sensory) nerve pathways is thought to be a major contributor to overactive bladder symptoms. Medications that target receptors on C-fibers are an active area of drug development.⁷

Diagnosis

NDO is a clinical diagnosis: it means detrusor overactivity confirmed on urodynamic testing in a person with a known neurological condition. The term “detrusor overactivity” itself replaced the older labels “detrusor instability” and “detrusor hyperreflexia,” which were considered confusing and unintuitive.⁸ Urodynamic testing involves filling the bladder through a catheter while pressure sensors record whether the detrusor muscle contracts involuntarily, how much volume the bladder holds, and how compliant the bladder wall is.

Some research has suggested that NDO can be distinguished from idiopathic overactive bladder based on the amplitude of the first involuntary contraction. One study found that using a pressure threshold of 30 cm of water for the first contraction gave an 88% chance of correctly identifying underlying neurological disease. That said, the two conditions can look identical on urodynamics in many cases, which is why the neurological history is essential to the diagnosis. You cannot diagnose NDO from the bladder tracing alone.

What Happens If NDO Goes Untreated

The consequences of unmanaged NDO go well beyond inconvenience. When the bladder contracts against a closed or uncoordinated outlet, pressures inside the bladder can rise dangerously high. Sustained high pressures get transmitted upstream to the kidneys, causing dilation of the renal pelvis and eventually kidney damage. Detrusor-sphincter dyssynergia, where the bladder neck and external sphincter tighten instead of relaxing when the bladder contracts, is one of the main drivers of this process. If untreated, DSD can cause severe and irreversible damage to both the upper and lower urinary tracts.⁹ The condition is associated with spinal cord injury, multiple sclerosis, and spina bifida, and affected patients face heightened risks for autonomic dysreflexia, recurrent urinary tract infections, and upper tract compromise.¹⁰

The risk of kidney damage is not the same across all causes. People with slowly progressive neurological conditions such as Parkinson’s disease or MS face considerably lower risk of upper urinary tract deterioration compared to those with spinal cord injury or spina bifida.¹¹ This distinction matters for how aggressively clinicians monitor kidney function: someone with a new spinal cord injury needs frequent imaging and urodynamic checks, while someone with early MS may be followed less intensively.

First-Line Medications

Anticholinergic drugs (also called antimuscarinics) are the standard first-line medical treatment for NDO. These medications work by blocking receptors on the bladder muscle that trigger contraction. A systematic review and meta-analysis of anticholinergic trials in NDO found that the drugs roughly tripled the odds of patient-reported cure or improvement compared to placebo, increased bladder capacity by about 50 ml, raised the volume at which the first involuntary contraction occurred, and lowered peak bladder pressure. Dry mouth was significantly more common with the medications, though withdrawal rates due to side effects were no different from placebo.¹² No single anticholinergic drug stood out as clearly better than the others in that analysis.

When a standard dose of one anticholinergic is not enough, combining two different agents at high doses is sometimes used. One study of this approach found that incontinence episodes dropped from an average of seven per day to one, bladder capacity roughly doubled, and bladder compliance improved substantially. Seven of the patients reported side effects and two stopped treatment because of them, but most tolerated the combination well.¹³

Mirabegron, a newer drug that relaxes the bladder through a different mechanism (it activates beta-3 receptors rather than blocking muscarinic ones), has been studied as an alternative. A randomized placebo-controlled trial in NDO patients found significant improvement in the volume at which the first involuntary contraction occurred and in bladder compliance, with patient-reported outcomes favoring mirabegron. Drug-related adverse events occurred in only about 3% of participants, giving it a better side-effect profile than most anticholinergics.¹⁴ A network meta-analysis comparing all available detrusor relaxing agents concluded that none of the anticholinergics or mirabegron was clearly superior to the others, though mirabegron had fewer bothersome side effects.¹⁵

Botulinum Toxin Injections

For people whose NDO does not respond adequately to oral medications, injections of onabotulinumtoxinA (Botox) directly into the bladder wall have become a mainstay treatment. A systematic review of the evidence found that roughly 40 to 80% of patients became completely dry between catheterizations after the injections, and peak bladder pressures dropped to safe levels in most studies, with no major adverse events.¹⁶

The effects of each injection last several months and then wear off, so repeat treatments are needed. A six-year follow-up study found that about 88% of patients were completely continent at that point, and cases of kidney dilation and urine reflux resolved entirely. Bladder capacity and contraction pressures remained significantly improved throughout.¹⁷ However, effectiveness does gradually decline for some people over the years. A large cohort study found that about 81% of patients were still receiving and responding to Botox at three years, dropping to about 71% at five years and 61% at seven years. The failure rate climbed from roughly 13% at three years to about 29% at seven years.¹⁸ So while Botox injections work well for the majority of patients across many years, they are not a permanent solution for everyone, and some will eventually need to explore other options.

Surgical Options When Other Treatments Fail

When medications and Botox injections are not enough, bladder augmentation surgery (augmentation cystoplasty) is the most established surgical approach. This operation involves using a segment of intestine to enlarge the bladder, increasing its capacity and reducing the pressures that threaten the kidneys. A systematic review of 20 studies found improved quality of life, stable kidney function, and better urodynamic parameters and continence rates across the board. Long-term complications continued up to ten years after surgery and included bowel dysfunction in about 15% of patients, bladder stones in about 10%, and rare but serious events such as bladder perforation and, in one case, bladder cancer.¹⁹

In adults with refractory NDO, augmentation ileocystoplasty has been shown to increase median bladder capacity from about 240 ml to 500 ml and substantially improve compliance, with continence rates rising from 7% preoperatively to 69% at a median of about two and a half years. The number of patients at risk for kidney damage dropped dramatically. Complications occurred in about 38% and included bowel dysfunction, bladder stones, metabolic acidosis, and autonomic dysreflexia.²⁰ In children with neurogenic bladder, a study reported that continence improved from about 23% before surgery to 82% afterward. Bladder stones developed in over a third of pediatric patients over long follow-up, and one child experienced a spontaneous perforation of the augmented segment.²¹ Because of these risks, augmentation cystoplasty is reserved for cases where less invasive treatments have failed and kidney health is at stake.

Living with NDO and Catheterization

Many people with NDO use clean intermittent catheterization (CIC) to empty the bladder on a schedule rather than relying on spontaneous voiding. CIC keeps bladder pressures low and helps prevent overdistension, but it comes with its own ongoing challenges, particularly urinary tract infections. A retrospective cohort study of neurogenic bladder patients using CIC found that about 12% experienced at least one symptomatic UTI, and the presence of detrusor overactivity was an independent risk factor, increasing UTI risk more than fivefold.²² In children with neurogenic bladder, additional risk factors for recurrent UTIs include older age, the presence of urine reflux into the kidneys, thickened bladder walls, and reduced bladder compliance.²³

Ongoing surveillance is a central part of living with NDO. Repeat urodynamic testing helps track whether bladder pressures are staying in a safe range, and periodic kidney imaging catches early signs of dilation or scarring before irreversible damage sets in. Medication regimens often need adjustment over time as the underlying neurological condition progresses or as bladder behavior changes.

Neuromodulation and Experimental Approaches

Neuromodulation, which involves electrical stimulation of the nerves that control the bladder, is well established for non-neurogenic overactive bladder and urinary retention but is a newer frontier for NDO. Sacral nerve stimulation and percutaneous tibial nerve stimulation have both been studied in neurogenic bladder patients. Evidence is still accumulating, and special considerations apply: for example, some patients with spinal cord injury have implanted hardware or altered pelvic anatomy that complicates device placement.²⁴

Further into the experimental pipeline, stem cell therapy is attracting attention for its potential to repair the damaged spinal cord itself rather than treating the bladder downstream. Animal studies using mesenchymal stem cells and neural stem cells have demonstrated improvements in bladder function after spinal cord injury, and early human clinical trials have reported promising changes in urodynamic measurements. The proposed mechanisms include stem cell differentiation into functional nerve cells and paracrine effects, where the transplanted cells release signaling molecules that promote repair in surrounding tissue.²⁵ These results are preliminary. Current treatments for NDO still focus on managing the bladder rather than reversing the neurological injury, and that reality is unlikely to change in the near term. But for people living with spinal cord injuries, the prospect of restoring some degree of normal bladder control by healing the cord itself is one of the more compelling long-term research goals in the field.